Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Rouff

Pain Medicine Yuma, AZ Medical Doctor

NPI 1609255512 CMS profile 6970674

2460 S Parkview Loop Ste 3, Yuma, AZ 85364

Open in the dashboard

General payments

$2,933

99 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mark Rouff of Yuma, AZ is reported in the CMS Open Payments database as having received $2,933 across 99 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 54th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $629 31
2024 General $374 19
2023 General $1,036 25
2022 General $150 2
2021 General $472 12
2020 General $225 7
2019 General $47 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Rouff
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Mark Rouff were reported at $629. Among 757 Pain Medicine profiles paid that year, the median was $470 and the middle half received between $146 and $1,462.

Show as a table
Year Mark Rouff Pain Medicine median Middle half National median
2019 $47 $506 $144–$1,566 $163
2020 $225 $315 $96–$934 $114
2021 $472 $452 $134–$1,237 $132
2022 $150 $475 $124–$1,407 $149
2023 $1,036 $480 $136–$1,384 $160
2024 $374 $521 $164–$1,511 $164
2025 $629 $470 $146–$1,462 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $1,947 61 payments
  2. Globus Medical, Inc. $352 15 payments
  3. Nevro Corp. $214 6 payments
  4. SI-BONE, Inc. $100 1 payment
  5. Abbott Laboratories $73 2 payments
  6. Stryker Corporation $41 1 payment
  7. Scilex Pharmaceuticals Inc. $36 2 payments
  8. Arbor Pharmaceuticals, Inc. $25 2 payments
  9. Vertex Pharmaceuticals Incorporated $23 1 payment
  10. Vertos Medical, Inc. $21 1 payment
  11. Other $102 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,593 97 payments
  2. Travel and Lodging $340 2 payments
Products named General payments · program years 2019–2025
  1. WaveWriter Alpha Prime 16 $413 22 payments
  2. GENERAL PAIN MANAGEMENT $225 5 payments
  3. Senza Spinal Cord Stimulator $181 8 payments
  4. Senza Spinal Cord Stimulator $176 4 payments
  5. Vyrsa V1 $171 7 payments
  6. WAVEWRITER ALPHA $148 3 payments
  7. IFUSE IMPLANT $100 1 payment
  8. Proclaim Family of SCS IPGs $73 2 payments
  9. General - Pain Management $56 1 payment
  10. SPINEJACK $41 1 payment
  11. Other $302 21 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

1,694

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$43,266

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

24.7%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Buprenorphine Generic 40 $9,827
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 213 $5,225
Celecoxib Generic 98 $4,370
Belbuca Buprenorphine Hcl Brand 11 $4,143
Gabapentin Generic 257 $3,311
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 142 $3,295
Diclofenac Sodium Generic 108 $2,925
Pregabalin Generic 67 $2,346
Tramadol Hcl Generic 239 $1,805
Baclofen Generic 169 $1,682

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$98,161

Medicare's payments for the services billed

Medicare patients

433

Average age 74

Services billed

1,399

265 women, 168 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 34%
Diabetes 32%
Chronic kidney disease 31%
Depression 30%
Osteoporosis 24%
COPD 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

99 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record